A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)

被引：1

作者：

Siena, S. ^{[1
]}

Sartore-Bianchi, A. ^{[1
]}

Karthaus, M. ^{[2
]}

Smith, D. ^{[3
]}

Garcia-Carbonero, R. ^{[4
]}

Van Cutsem, E. ^{[5
]}

Guan, X. ^{[6
]}

Boedigheimer, M. ^{[7
]}

Sidhu, R. ^{[8
]}

Jung, A. S. ^{[8
]}

Oliner, K. S. ^{[9
]}

Tabernero, J. ^{[10
]}

Bardelli, A. ^{[11
]}

机构：

[1] Osped Niguarda Ca Granda, Niguarda Canc Ctr, Milan, Italy

[2] Klinikum Harlaching, Med Oncol, Klinikum Neuperlach, Munich, Germany

[3] Hop St Andre, Med Oncol, Bordeaux, France

[4] Univ Hosp, Med Oncol, Seville, Spain

[5] Univ Hosp Gasthuisberg, Digest Oncol, Leuven, Belgium

[6] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA

[7] Amgen Inc, Mol Sci & Computat Biol, Thousand Oaks, CA 91320 USA

[8] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA

[9] Amgen Inc, Med Sci, Thousand Oaks, CA 91320 USA

[10] VHIO, Barcelona, Spain

[11] Fdn Piemonte Oncol IRCCS, Ist Candiolo, Candiolo, Italy

来源：

关键词：

D O I：

10.1016/S0959-8049(16)31104-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2184

引用

页码：S394 / S395

页数：2